0001415889-23-016896.txt : 20231222 0001415889-23-016896.hdr.sgml : 20231222 20231222161355 ACCESSION NUMBER: 0001415889-23-016896 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20231214 FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thakkar Roopal CENTRAL INDEX KEY: 0002004979 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 231509929 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 3 1 form3-12222023_091246.xml X0206 3 2023-12-14 0 0001551152 AbbVie Inc. ABBV 0002004979 Thakkar Roopal 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false SVP, Global Therapeutics & CMO Common Stock, $0.01 par value 30225 D Option (Right to buy) 93.50 2021-02-20 2030-02-19 Common Stock 18003 D Option (Right to buy) 105.92 2022-02-18 2031-02-17 Common Stock 7763 D Option (Right to buy) 144.54 2023-02-17 2032-02-16 Common Stock 7005 D Option (Right to buy) 149.62 2024-02-16 2033-02-15 Common Stock 8102 D Includes 6,918 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 6,001 shares on 02/20/2021, as to 6,001 shares on 02/20/2022, and as to 6,001 shares on 02/20/2023. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,588 shares on 02/18/2022 and as to 2,588 shares on 02/18/2023, and will become exercisable as to as to 2,587 shares on 02/18/2024. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,335 shares on 02/17/2023, and will become exercisable as to 2,335 shares on 02/17/2024 and as to 2,335 shares on 02/17/2025. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,701 shares on 02/16/2024, as to 2,701 shares on 02/16/2025 and as to 2,700 shares on 02/16/2026. T.O. Odutayo, Attorney-in-Fact for Roopal Thakkar 2023-12-22 EX-24 2 ex24-12222023_091246.htm ex24-12222023_091246.htm


POWER OF ATTORNEY


The undersigned constitutes and appoints PERRY C. SIATIS,  EMILY A. WEITH, and T.O. ODUTAYO, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission  ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities  Act of 1933, as amended (the “Securities Act”), on Form 144, any and all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all other forms and reports required or permitted to be filed or signed by the undersigned under the Securities Act or the Exchange Act, to the extent permitted by law, as well as a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments or successors to such forms or reports, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.


A copy of this power of attorney shall be filed with the SEC.  The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.




Date:  December 15, 2023


/s/ Roopal Thakkar

Roopal Thakkar



AbbVie Inc.

1 N. Waukegan Road

North Chicago, IL   60064